Forecast for Immune Thrombocytopenia Market Shows Sustained Growth with Innovations in Treatment Options Until 2036

Immune Thrombocytopenia Market Overview

The immune thrombocytopenia (ITP) market is on an upward trajectory, bolstered by growing awareness about the disease and enhancements in diagnostic protocols. Recent breakthroughs in targeted therapies, such as thrombopoietin receptor agonists and innovative immunomodulators, are broadening treatment avenues and yielding better patient outcomes. The rise of new therapies including Ianalumab from Novartis, Rozanolixizumab from UCB Biopharma, and Mezagitamab from Takeda showcases this growth. These emerging solutions not only offer improved safety but also foster efficacy, further accelerating the market’s expansion.

Key Developments and Market Insights

According to a recently published report by DelveInsight, the ITP market size across the seven major markets (7MM)—comprising the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan—was valued at approximately USD 4 billion in 2025, with expectations for significant growth by 2036. The United States holds the largest share, accounting for nearly 66% of the market in 2025. With an estimated 188,000 cases of ITP reported in 2025 across the 7MM, this number is projected to rise over the next decade.

Several key pharmaceutical companies, including Novartis, Takeda, and Pfizer, are actively working on innovative treatments to address unmet needs in ITP management. Notably, therapies currently under development, such as Ianalumab, Rozanolixizumab, Mezagitamab, and others, are entering crucial clinical phases, showing promise for reshaping treatment paradigms in ITP.

Factors Driving Market Growth

1. Rising Incidence of Autoimmune Disorders: With a notable increase in immune thrombocytopenia and coexisting autoimmune diseases like lupus and rheumatoid arthritis, the demand for effective treatments is rising significantly.

2. Innovative Drug Mechanisms: The introduction of drugs like TAVALISSE/TAVLESSE, a Syk inhibitor, offers a groundbreaking mechanism to combat severe thrombocytopenia, enhancing immunological responses.

3. Emerging Therapies: The anticipated launches of novel treatments such as WAYRILZ mark key advancements in chronic ITP therapeutic options. As a BTK inhibitor, rilzabrutinib addresses critical treatment gaps for adults who have not responded well to previous therapies.

4. New Classes of Drugs: The arrival of innovative drug categories, including BAFF-R inhibitors and anti-CD38 antibodies, is set to further stimulate market demand and transform ITP treatment landscapes.

Current Treatment Landscape

Historically, the treatment approach for ITP has revolved around immune-modulating therapies like corticosteroids, IVIGs, splenectomy, and rituximab. However, the therapeutic framework has expanded to encompass newer treatments such as thrombopoietin receptor agonists (e.g., PROMACTA, NPLATE, DOPTELET) and Syk inhibitors, alongside various immunomodulatory therapies.

The recent approval of WAYRILZ by Sanofi is a transformative milestone within the ITP market, marking the first BTK inhibitor authorized for this condition. Based on results from pivotal LUNA 3 Phase III trials, WAYRILZ demonstrated significant platelet responses, presenting a valuable addition to the ITP treatment arsenal.

Moreover, therapies like VYVGART, which recently secured approval in Japan for adult primary ITP patients, are expected to raise competitive standards by providing favorable and sustained platelet responses.

Emerging Therapeutics in Development

As the timeline progresses into the forecast period, multiple late-stage candidates—such as Ianalumab, Rozanolixizumab, Mezagitamab, PF-06835375, and others—are on track to culminate in transformative launches that promise to redefine the management and care of ITP patients. For instance, Novartis' Ianalumab is currently undergoing Phase III trials and could provide substantial patient benefits based on its targeted mechanism of action. Likewise, Takeda’s Mezagitamab and Pfizer’s PF-06835375 are anticipated to innovate treatment strategies aimed at improving patient outcomes.

Conclusion

The landscape for the immune thrombocytopenia market is transforming dramatically, with a multitude of emerging therapies promising enhanced treatment options amid rising awareness of ITP and associated disorders. As the industry progresses, medical professionals and stakeholders will observe the profound impact that these therapies will have on patient management and overall care for individuals suffering from ITP. The advancements herald a new era of opportunities for research, economic growth, and improved healthcare delivery in terms of chronic illness management and patient-centered care strategies.

For detailed insights on the immune thrombocytopenia market, visit the DelveInsight report.